... to the prediction of responses to therapy using antibodies to tumor necrosis factor (anti-TNF). Key Messages: Several in vivo imaging studies have been performed in IBD patients before and after anti-TNF therapy. In one study, (99m)Technetium-labeled annexin V was given to patients with active Crohn's disease...

... on a diagnosis of IBD and cancer with subsequent exposure to anti-tumor necrosis factor α (anti-TNFα arm), thiopurines or methotrexate (antimetabolite arm) or without subsequent IS exposure (control arm). Two hundred and fifty-five patients met the inclusion criteria. Prior cancers included 121 solid, 62...

...Shomron Ben-Horin The management of patients with inflammatory bowel disease (IBD) presenting with loss of response (LOR) to anti-tumor necrosis factor (TNF) biologics is an increasingly encountered challenge for clinicians caring for these patients. Clinical decisions are complicated by the lack...

... or therapeutic concepts against HCC. Tumor necrosis factor (TNF) is a cytokine derived from monocytes and various other immunological and parenchymal cells. Upon binding to its receptors, TNF activates different signaling cascades including the pro-apoptotic caspase cascade as well as inflammatory and stress...

... Biology Research, Novo Nordisk, Gentofte, and Laboratory of Medical Immunology, Department of Medicine TTA, Rigshospitalet, University of Copenhagen, Denmark Key Words Crohn s disease Cyclosporin Cytokines Inflammatory bowel disease Interleukins Mesalazine Ulcerative colitis Tumor necrosis factor...

...Pal Miheller; Gyorgyi Müzes; Tamas Zagoni; Miklos Toth; Karoly Racz; Zsolt Tulassay Background: Tumor necrosis factor-α (TNF-α) plays a pivotal role in the pathogenesis of inflammatory bowel diseases and bone resorption as well. Limited data exist about the effect of anti-TNF-α infliximab on bone...